Corporate Information, English, IR, Listing Regulation, News, Other Corporate Information, Regulatory

Acarix AB changes Certified Adviser to Tapper Partners AB

  • Posted by author-avatar
24 Oct

Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, today announce that the company is changing its Certified Adviser to Tapper Partners AB.

Tapper Partners AB will assume the role of Certified Adviser on November 1, 2025. Until then, DNB Carnegie Investment Bank AB will continue to act as the company’s Certified Adviser.

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 40,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

For more information, contact
Macie May, phone +1 405 517 5161, email mmay@saxum.com

Attachments
Acarix AB changes Certified Adviser to Tapper Partners AB

Acarix AB changes Certified Adviser to Tapper Partners AB
Back to list
Older Acarix responds to G-BA decision on reimbursement in the German market